A proposed class-action lawsuit has been filed against five Canadian pharmaceutical companies alleging the firms may have been negligent in their manufacturing of the drugs and in quality control testing of raw material from their supplier in China.
On July 10, Health Canada recalled 28 blood pressure medications from five generic brands that use the ingredient valsartan. The Chinese firm that produces valsartan reported a contamination with N-nitrosodimethylamine (NDMA), which the International Agency for Research on Cancer has classified as a probable human cancer causing agent.
Zhejiang Huahai Pharmaceuticals, the Chinese company involved in the contamination, did not respond to a request for comment from CTV News.
No comments:
Post a Comment